Drawing for MICROMOD MODULAR DESIGNED PARTICLES

USPTO serial 79362814

MICROMOD MODULAR DESIGNED PARTICLES

Reviewed by CopyMark Law Group

Reg. 7601873Status 700Registered
Filing date
Status date
Registration date
Dec 17, 2024
Examiner
SAITO, KIM
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MICROMOD MODULAR DESIGNED PARTICLES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Biochemicals for in vitro and in vivo scientific applications; biochemical products, namely, polypeptides for in vitro research applications; carboxymethyl cellulose; chemicals for use in the purification of proteins for in vitro applications; chemical diagnostic reagents, other than for medical or veterinary use; chemicals used for industrial and scientific purposes; unprocessed chemical polymers; chemical preparations for the manufacture of surface coatings; chemical reagents for molecular biology, other than for medical or veterinary uses; chemical substances for modifying the properties of polymers; chemical additives for polymers; copolymers for manufacturing and industrial use; diagnostic preparations for scientific or research use; diagnostic reagents for in vitro use other than for medical purposes; iron oxide; fluid polymers for industrial use; glucose polymers for industrial use; hemicellulose; hydrogel polymer coating agents for manufacturing and industrial use; hydrolysed starches for industrial use; hydroxyethyl methyl cellulose; hydroxypropyl methyl cellulose acetate succinate; hydroxypropyl methyl cellulose phthalate; cationic polymers for manufacturing and industrial use; methacrylates; methyl cellulose; lactic acid polymers for manufacturing and industrial use; modified starches for industrial use; natural starches for industrial use; low-substituted hydroxypropyl cellulose; polyamides; polyelectrolytes for manufacturing and industrial use; polyether polyols for manufacturing and industrial use; unprocessed polyethylene resins; polymer coatings other than paints; water-based polymer dispersions for industrial uses; polymers for the analysis of nucleic acids; polymers for the analysis of proteins; polymers for the analysis of biochemical products; polymers for the analysis of organic chemicals; unprocessed polymers for manufacturing; industrial polymer emulsifiers; polymer solutions for manufacturing and industrial use; polymer beads for manufacturing; polyol organic compound; polypeptides for scientific purposes; unprocessed polypropylene; polyurethane coatings other than paints; polyurethanes; silicates for industrial purposes; stabilisers for plastic polymers; styrene; styrene monomers; synthetic polymers in the crude state; polyester triols for the preparation of high performance industrial coatings; unprocessed polystyrene; polymer-based compounds for manufacturing processes; reinforced polymers for manufacturing and industrial useACTIVE
005Biological reagents for medical purposes; biological reagents for veterinary purposes; chemical diagnostic reagents for medical purposes; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; diagnostic biomarker reagents for medical purposes; diagnostic substances for medical purposes; in vitro diagnostic preparations for medical purposes; indicators for medical diagnosis being diagnostic preparations for medical purposes; clinical medical reagents; medical diagnostic agents; reagents for analytical purposes for medical purposes; reagents for in vitro laboratory tests for medical purposes; reagents for in vitro laboratory purposes for veterinary purposes; reagents for clinical medical diagnosis; reagents and media for medical and veterinary diagnostic purposes; reagents for medical diagnosis; reagents for veterinary diagnosisACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 6, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB
May 19, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB
May 19, 2025FIMPFINAL DISPOSITION PROCESSED
Mar 17, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 17, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 15, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 25, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 6, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2024XAECEXAMINER'S AMENDMENT ENTERED
Aug 8, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 8, 2024GNEAEXAMINERS AMENDMENT E-MAILED
Aug 8, 2024CNEAEXAMINERS AMENDMENT -WRITTEN
Aug 3, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 15, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 14, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 9, 2024XAECEXAMINER'S AMENDMENT ENTERED
Jul 9, 2024ALIEASSIGNED TO LIE
Jul 1, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 1, 2024GNEAEXAMINERS AMENDMENT E-MAILED
Jul 1, 2024CNEAEXAMINERS AMENDMENT -WRITTEN
Jun 3, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 26, 2023RFNTREFUSAL PROCESSED BY IB
Dec 4, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 4, 2023RFRRREFUSAL PROCESSED BY MPU
Dec 4, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 3, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 19, 2023DOCKASSIGNED TO EXAMINER
Feb 21, 2023MAFRAPPLICATION FILING RECEIPT MAILED
Feb 17, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 16, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance